What is the only pharmacotherapy with an FDA indication to treat binge-eating disorder?

Lisdexamfetamine dimesylate is recognized as the only pharmacotherapy with an FDA indication specifically for the treatment of binge-eating disorder. This medication was approved because clinical studies demonstrated its effectiveness in reducing binge-eating episodes in individuals diagnosed with this disorder. Lisdexamfetamine is a stimulant that works by affecting neurotransmitters in the brain, which can help to control impulsive behaviors associated with binge eating.

While other medications, such as fluoxetine and sertraline, are often used for the treatment of various eating disorders and might help with symptoms of binge-eating disorder, they are not specifically approved by the FDA for this purpose. Topiramate has been studied for binge eating but lacks specific FDA approval for this indication. Therefore, lisdexamfetamine dimesylate stands out as the only medication with a designated indication, making it a key treatment option for clinicians addressing binge-eating disorder.